CLPBF (Coloplast AS) EBIT : $1,053 Mil (TTM As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Coloplast AS EBIT?

Coloplast AS's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $267 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $1,053 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Coloplast AS's annualized ROC % for the quarter that ended in Sep. 2024 was 13.61%. Coloplast AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 67.44%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Coloplast AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 3.60%.

Coloplast AS EBIT Historical Data

The historical data trend for Coloplast AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast AS EBIT Chart

Coloplast AS Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

EBIT

Get a 7-Day Free Trial

870.32

990.10

837.97

953.53

1,070.26

Coloplast AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															245.29	252.82	263.57	269.41	267.34

Competitive Comparison of Coloplast AS's EBIT

For the Medical Instruments & Supplies subindustry, Coloplast AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coloplast AS's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Coloplast AS's EV-to-EBIT falls into.

Coloplast AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,053 Mil.

Coloplast AS (OTCPK:CLPBF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Coloplast AS's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	1073.532 * ( 1 - 18.03% )	/	( (6526.335	+	6404.138)	/ 2 )
=	879.9741804	/	6465.2365
=	13.61 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7006.461	-	743.337	-	( 127.928	-	max(0, 1797.767	-	1534.556	+	127.928	))
=	6526.335

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	7155.85	-	715.987	-	( 117.297	-	max(0, 1518.904	-	1554.629	+	117.297	))
=	6404.138

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Coloplast AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	1069.364	/	( ( (927.945 + max(606.611, 0))	+	(978.118 + max(658.53, 0)) )	/	2 )
=	1069.364	/	( ( 1534.556	+	1636.648 )	/	2 )
=	1069.364	/	1585.602
=	67.44 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(697.329	+	530.172	+	136.725)	-	(743.337	+	0	+	14.278)
=	606.611

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(695.892	+	546.591	+	140.369)	-	(715.987	+	0	+	8.335)
=	658.53

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Coloplast AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	1053.143	/	29273.146
	=	3.60 %

Coloplast AS EBIT Related Terms

Thank you for viewing the detailed overview of Coloplast AS's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Coloplast AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast AS (OTCPK:CLPBF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

CLPBY:USA COLOBc:UK 0QBO:UK COLO B:Denmark CBH:Germany

Address

Holtedam 1-3, Humlebaek, DNK, DK-3050

Website

https://www.coloplast.com

Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.